InvestorsHub Logo
Followers 22
Posts 1797
Boards Moderated 0
Alias Born 11/22/2015

Re: Renee post# 11247

Tuesday, 09/19/2017 10:34:45 AM

Tuesday, September 19, 2017 10:34:45 AM

Post# of 18666

"Since neurological diseases are disorders of the brain, spinal cord and nerves throughout the body, Dr. Chase’s background could be pivotal when it comes to the further development of GT Biopharma (OXISD)’s GTP-004. This is a treatment for myasthenia gravis, which is a rare muscular disease triggered by antibodies that attack certain parts of muscles."



From the Huffington article today: http://www.huffingtonpost.com/entry/another-big-name-in-biotech-heads-to-gt-biopharma-inc_us_59c11277e4b082fd4205b9af
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GTBP News